Silk Road Medical Names Chas McKhann Chief Executive Officer
02 Novembro 2023 - 9:00AM
Silk Road Medical, Inc. (Nasdaq: SILK) (“Silk Road” or the
“Company”), a company focused on reducing the risk of stroke and
its devastating impact, today announced that Chas McKhann has been
appointed Chief Executive Officer (CEO), effective immediately.
Mr. McKhann is an accomplished leader with more than 25 years of
experience in the medical device industry, including C-suite
positions at seven public and private companies. Most recently, Mr.
McKhann served as President and CEO of Apollo Endosurgery (acquired
by Boston Scientific in April 2023), where he created and led a
transformational growth strategy for the company’s minimally
invasive technologies for gastrointestinal and bariatric
conditions. Previously, he held leadership positions at Torax
Medical and Intersect ENT, among others.
“Chas is a skilled and experienced leader with a track record of
effectively building and scaling medical device businesses into
underpenetrated markets. We are excited to welcome him to Silk
Road,” said Jack Lasersohn, Chairman of the Board of Directors. “We
thank Erica Rogers for her leadership and contributions to Silk
Road over the last 11 years, and we look forward to our next phase
of growth as we continue expanding the use of Transcarotid Artery
Revascularization (TCAR).”
“I am thrilled to join Silk Road Medical as the company’s CEO,”
said Mr. McKhann. “I look forward to working closely with the
leadership team and Board of Directors to build upon Silk Road’s
track record of growth, advance the company’s progress toward
establishing TCAR as the minimally invasive standard of care in
carotid artery disease, and continue delivering on the company’s
mission to reduce the risk of stroke and its devastating impact for
patients.”
“The Board and I are confident that Chas is the right leader to
leverage our strong operational infrastructure, skilled commercial
team, and substantial body of clinical evidence to take the company
further on the journey to treat patients with carotid artery
disease. Under his leadership, Silk Road remains committed to the
same mission, vision, and values that have guided it since its
founding. We look forward to executing a smooth transition and
continue expanding our impact for patients at risk of stroke,”
added Mr. Lasersohn.
Mr. McKhann succeeds Erica Rogers, who has now retired from the
President and CEO role and will continue as an advisor to the
Company’s Board of Directors.
About Chas McKhannBefore joining Silk Road, Mr.
McKhann was President and CEO of Apollo Endosurgery where he
created and led a transformational growth strategy for the
company’s minimally invasive technologies for gastrointestinal and
bariatric conditions. He led the company through multiple product
approvals through the FDA De Novo pathway and oversaw the company’s
successful sale to Boston Scientific, which closed in April
2023.
Prior to Apollo, Mr. McKhann was Chief Commercial Officer at Rox
Medical, where he developed a global commercial strategy for a
novel therapy for hypertension and supported clinical trial
enrollment in advance of regulatory clearance. Mr. McKhann was
previously Chief Commercial Officer at Torax Medical, acquired by
Johnson & Johnson in 2017, and Intersect ENT, which was later
acquired by Medtronic in 2022.
Previously, Mr. McKhann was CEO at Apnex Medical, a developer of
a hypoglossal nerve stimulator for obstructive sleep apnea, global
head of marketing of cardiac rhythm management at Boston
Scientific, and Director of Marketing at Cordis, a unit of Johnson
& Johnson, where he was the marketing lead for CYPHER®, a
sirolimus-eluting coronary stent that was the first cardiac
drug-eluting stent. Mr. McKhann began his career as a strategy
consultant at SCA Consulting and McKinsey & Company. He holds a
BA in Political Science and an MBA from Stanford University.
About Silk Road Medical
Silk Road Medical, Inc. (NASDAQ: SILK) is a medical device
company located in Sunnyvale, California, and Plymouth, Minnesota
that is focused on reducing the risk of stroke and its devastating
impact. The company has pioneered a new approach for the treatment
of carotid artery disease called TransCarotid Artery
Revascularization (TCAR). TCAR is a clinically proven procedure
combining surgical principles of neuroprotection with minimally
invasive endovascular techniques to treat blockages in the carotid
artery at risk of causing a stroke. For more information on how
Silk Road Medical is delivering brighter patient outcomes through
brighter clinical thinking, visit www.silkroadmed.com and connect
on Twitter, LinkedIn, and Facebook.
Forward-Looking Statements
Statements contained in this release that relate to future, not
past, events are forward-looking statements under the Private
Securities Litigation Reform Act of 1995, including the Company’s
expectations for a smooth new CEO transition and future growth
expectations. Forward-looking statements are based on current
expectations of future events and often can be identified by words
such as “plan,” “expect,” “should,” “project,” “anticipate,”
“intend,” “will,” “can,” “may,” “believe,” “could,” “continue,”
“future,” “look forward,” and other words of similar meaning or the
use of future dates. Forward-looking statements by their nature
address matters that are, to different degrees, uncertain. Risks
and uncertainties may cause Silk Road Medical’s actual results to
be materially different than those expressed in or implied by Silk
Road Medical’s forward-looking statements. For Silk Road Medical,
such risks and uncertainties include, among others, risks
surrounding the CEO transition, the Company’s success in retaining
and recruiting key personnel, and the Company’s ability to continue
to grow the business and expand the use of TCAR. More detailed
information on these and other factors that could affect Silk Road
Medical’s actual results are described in its filings with the U.S.
Securities and Exchange Commission, including its most recent
quarterly report on Form 10-Q filed with the Securities and
Exchange Commission on August 8, 2023. Silk Road Medical undertakes
no obligation to update its forward-looking statements.
Investor Contact:Marissa BychGilmartin Group
LLCinvestors@silkroadmed.com
Media:Michael FanucchiSilk Road
Medicalmfanucchi@silkroadmed.com
Silk Road Medical (NASDAQ:SILK)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Silk Road Medical (NASDAQ:SILK)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024